|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Longevity Internal Elixir—Tradition of Yue School in East Sichuan for Warding off Disease, Keeping in Good Health and Cultivating Mind显示文摘With the continuous improvement of the national economy and people's quality of life, people's attention to human health and health is increasing. Taking exercise and reasonable diet and good living habits to adjust the body's meridian operation and promote the continuous optimization of human body function is an important way to achieve healthy development and optimize people's lifestyle. This paper describes the formation and development of Longevity Internal Elixir form Yue School in East Sichuan and its positive effects on human health. It analyzes the implementation methods and steps of Longevity Internal Elixir and points out the precautions and safeguards for the implementation of Longevity Internal Elixir. Through the analysis of this paper, it is clear that Longevity Internal Elixir plays an important role in the health of the people, exerts its role in promoting bodily functions. The implementation methods and safeguard measures of Longevity Internal Elixir are also clarified in this paper. | Grace·Tan | 2018 | Journal of Advances in Medicine Science2018，1，4： | 0 |
| 2 | Liposomes in double - emulsion globules 显示文摘 | WANG QING TAN GRACE LAWSON L B | 2010 | Langmuir2010，26，5： | 1 |
| 3 | Synthesis of me soporous carbon using enzymatically polymerized polyphe nolle precursor and simultaneously assembled silica tern plalc显示文摘 | Jiehin Pang Christy Ford Grace Tan | 2005 | Micruporous and mesoporous materials2005，85，： | 1 |
| 4 | Surgicalmanagement of placenta accreta: a 10-year experience显示文摘 | Grace Tan SE Jobling TW Wallace EM | 2013 | ActaObstet Gynecol Scand2013，92，4： | 1 |
| 5 | Surgicalmanagement of placenta accreta : a 10-year experience 显示文摘 | Grace Tan SE Jobling TW Wallace EM | 2013 | ActaObstet Gynecol Scand2013，92，4： | 1 |
| 6 | Risk Perceptions and Barriers to Hepatitis B Screening and Vaccination among Vietnamese Immigrants显示文摘 | Grace X. Ma Carolyn Y. Fang Steven E. Shive Jamil Toubbeh Yin Tan Philip Siu | 2007 | Journal of Immigrant and Minority Health2007，，3： | 1 |
| 7 | Palliative surgery for Krukenberg tumors—12-year experience and review of the literature显示文摘AIM To determine the clinical characteristics of patients undergoing palliative surgery for Krukenberg tumors,including disease presentation,outcomes,and prognostic factors.METHODS This was a retrospective clinical study of all patients who underwent palliative surgery for Krukenberg tumors between January 2004 and December 2015.Patient information was obtained from inpatient and outpatient case notes as well as the hospital electronic records.Patients who underwent potential y curative resection,and patients with Krukenberg tumors who did not undergo surgery were also excluded from the study.Palliative surgery was defined as those performed for either alleviation of symptoms or for asymptomatic patients for whom surgical removal of the tumors were deemed necessary following a multidisciplinary consensus.Tumors were diagnosed pre-operatively by computed tomography scans and all had histologic confirmation of the surgical specimens.RESULTS Over the study duration,38 female patients underwent palliative surgery for Krukenberg tumors at our institution.Mean age was 54.2±11.7 years.The colon was the most frequent primary source of metastases(n=21)followed by the stomach(n=4).Prophylactic palliative surgery was performed for eight(21.1%)asymptomatic patients.Median post-operative length of stay was 8 d(IQR 6-12 d).Five patients(13.2%)experienced postoperative complications,although high grade morbidity was only seen in one patient(2.6%).Median overall survival from surgery was 17 mo(95%CI:12.1-21.9)at a median follow-up duration of 12 mo(IQR 8-17mo).The median survival was shorter for patients who underwent emergency surgery,younger patients,those with a colorectal primary,larger tumors,or synchronous peritoneal or hepatic metastases.CONCLUSION Pal iative surgery for Krukenberg tumors can be performed safely with acceptable complication rates.Bilateral oophorectomy should be performed to prevent the risk of symptomatic contralateral tumors. | Isaac Seow-En Gwen Hwarng Grace Hwei Ching Tan Leonard Ming Li Ho Melissa Ching Ching Teo | 2018 | World Journal of Clinical Oncology2018，9，1： | 5 |
| 8 | Dispersion of Titanium(Ⅳ) Oxide Nanoparticles in Mixed Matrix Membrane Using Octaisobutyl Polyhedral Oligomeric Silsesquioxane for Enhanced CO2/CH4 Separation Performance显示文摘Titanium(IV) oxide (TiO2) nanoparticles have been incorporated into mixed matrix membranes (MMMs) to improve gas separation performance. However, TiO2 nanoparticles tend to agglomerate due to high surface energy and van der Waals forces. This leads to precipitation which causes the formation of non-homogeneous MMM morphology. In this study, the effect of octaisobutyl polyhedral oligomeric silsesquioxane (POSS) addition on TiO2/polysulfone MMM was investigated. The aims are to enhance gas separation performance whilst preventing agglomeration of TiO2 nanoparticles. The results demonstrated that inclusion of POSS as dispersant increases MMMs’ CO2/CH4 selectivity and permeance, possibly due to less void formation and more evenly distributed pore structure. For example, synergistic addition of 5 wt% TiO2 and 5 wt% POSS increased the CO2/CH4 selectivity up to 390% compared to MMM without POSS. This is supported by elemental mapping of titanium which revealed that POSS successfully dispersed TiO2 nanoparticles and prevented aggregation. TiO2-POSS/PSf MMMs also retained their favorable thermal stability. | Grace Ying En Tan Pei Ching Oh Kok Keong Lau Siew Chun Low | 2019 | Chinese Journal of Polymer Science2019，37，7： | 0 |
| 9 | Mechanisms of hepatocellular carcinoma progression显示文摘Hepatocellular carcinoma(HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells,immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed. | Olorunseun O Ogunwobi Trisheena Harricharran Jeannette Huaman Anna Galuza Oluwatoyin Odumuwagun Yin Tan Grace X Ma Minhhuyen T Nguyen | 2019 | World Journal of Gastroenterology2019，25，19： | 21 |
| 10 | Spatial-Temporal [ 18 F]FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiation Therapy显示文摘 | Shan Tan Seth Kligerman Wengen Chen Minh Lu Grace Kim Steven Feigenberg Warren D. D’Souza Mohan Suntharalingam Wei Lu | 2012 | International Journal of Radiation Oncology Biology Physics2012，，： | 1 |
| 11 | The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)显示文摘Objective:Cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemotherapy(HIPEC)are increasingly being used to treat peritoneal malignancies.Urological resections and reconstruction(URR)are occasionally performed during the surgery.We aim to evaluate the impact of these procedures on peri-operative outcomes of CRS and HIPEC patients.Methods:A retrospective review of a prospectively maintained database of all patients who underwent CRS-HIPEC from April 2001 to February 2016 was performed.Outcomes between patients who had surgery involving,and not involving URR were compared.Primary outcomes were the rate of major complications and the duration of stay in the intensive care unit(ICU)and hospital.Secondary outcomes were that of overall survival(OS)and prognostic factors that would indicate a need for URR.Results:A total of 214 CRS-HIPEC were performed,21 of which involved a URR.Baseline clinical characteristics did not vary between the groups(URR vs.No URR).Urological resections comprised of 52%bladder resections,24%ureteric resections,and 24%involving both bladder and ureteric resections.All bladder defects were closed primarily while ureteric reconstructions consisted of two end-to-end anastomoses,one ureto-uretostomy,five direct implantations into the bladder and three boari flaps.URR were more frequently required in patients with colorectal peritoneal disease(p Z 0.029),but was not associated with previous pelvic surgery(76%vs.54%,p Z 0.065).Patients with URR did not suffer more serious complications(14%vs.24%,p Z 0.42).ICU(2.2 days vs.1.4 days,p Z 0.51)and hospital stays(18 days vs.25 days,p Z 0.094)were not significantly affected.Undergoing a URR did not affect OS(p Z 0.99),but was associated with increased operation time(570 min vs.490 min,p Z 0.046).Conclusion:While concomitant URR were associated with an increase in operation time,there were no significant differences in postoperative complications or OS.Patients with colorectal peritoneal metastases are more likely to require a URR compared to other primary tumours,and needs to be considered during pre-operative planning. | Grace Hwei Ching Tan Nicholas B.Shannon Claramae Shulyn Chia Lui Shiong Lee Khee Chee Soo Melissa Ching Ching Teo | 2018 | Asian Journal of Urology2018，5，3： | 1 |
| 12 | Management of synchronous lateral pelvic nodal metastasis in rectal cancer in the era of neoadjuvant chemoradiation: A systemic review显示文摘BACKGROUND Lateral pelvic lymph node(LLN)metastasis(LLNM)occur in up to 28%of patients with low rectal tumours.While prophylactic lateral pelvic lymph node dissection(LLND)has been abandoned by most western institutions in the era of neoadjuvant chemoradiation therapy(CRT),the role of selective LLND in patients with enlarged LLN on pre-CRT imaging remains unclear.Some studies have shown improved survival and recurrence outcomes when LLNs show'response'to CRT.However,no management algorithm exists to differentiate treatment for'responders'vs'non-responders'.AIM To determine if selective LLND in patients with enlarged LLNs results in improved survival and recurrence outcomes.METHODS A systemic search of Pub Med and Embase databases for studies reporting on patients with synchronous radiologically suspicious LLNM(s-LLNM)in rectal cancer receiving preoperative-CRT was performed.RESULTS Fifteen retrospective,single-centre studies were included.793 patients with sLLNM were evaluated:456 underwent TME while 337 underwent TME with7,LLND post-CRT.In the TME group,local recurrence(LR)rates range from 12.5%to 36%.Five-year disease free survival(DFS)was 42%to 75%.In the TME with LLND group,LR rates were 0%to 6%.Five years DFS was 41.2%to 100%.Radiological response was seen in 58%.Pathologically positive LLN was found in up to 94%of non-responders vs 0%to 20%in responders.Young age,low tumour location and radiological non-response were associated with final positive LLNM and lowered DFS.CONCLUSION LLND is associated with local control in patients with s-LLNM.It can be performed in radiological non-responders given a large majority represent true LLNM.Its role in radiological responders should be considered in selected high risk patients. | Jolene Si Min Wong Grace Hwei Ching Tan Claramae Shulyn Chia Chin-Ann Johnny Ong Melissa Ching Ching Teo | 2020 | World Journal of Gastrointestinal Surgery2020，12，5： | 0 |
| 13 | Gastric peritoneal carcinomatosis-a retrospective review显示文摘AIM To characterize patients with gastric peritoneal carcinomatosis(PC) and their typical clinical and treatment course with palliative systemic chemotherapy as the current standard of care.METHODS We performed a retrospective electronic chart review of all patients with gastric adenocarcinoma with PC diagnosed at initial metastatic presentation between January 2010 and December 2014 in a single tertiary referral centre.RESULTS We studied a total of 271 patients with a median age of 63.8 years and median follow-up duration of 5.1 mo. The majority(n = 217, 80.1%) had the peritoneum as the only site of metastasis at initial presentation. Palliative systemic chemotherapy was eventually planned for 175(64.6%) of our patients at initial presentation, of which 171 were initiated on it. Choice of first-line regime was in accordance with the National Comprehensive Cancer Network Guidelines for Gastric Cancer Treatment. Thesepatients underwent a median of one line of chemotherapy, completing a median of six cycles in total. Chemotherapy disruption due to unplanned hospitalizations occurred in 114(66.7%), while cessation of chemotherapy occurred in 157(91.8%), with 42 cessations primarily attributable to PC-related complications. Patients who had initiation of systemic chemotherapy had a significantly better median overall survival than those who did not(10.9 mo vs 1.6 mo, P < 0.001). Of patients who had initiation of systemic chemotherapy, those who experienced any disruptions to chemotherapy due to unplanned hospitalizations had a significantly worse median overall survival compared to those who did not(8.7 mo vs 14.6 mo, P < 0.001).CONCLUSION Gastric PC carries a grim prognosis with a clinical course fraught with disease-related complications which may attenuate any survival benefit which palliative systemic chemotherapy may have to offer. As such, investigational use of regional therapies is warranted and required validation in patients with isolated PC to maximize their survival outcomes in the long run. | Hwee Leong Tan Claramae Shulyn Chia Grace Hwei Ching Tan Su Pin Choo David Wai-Meng Tai Clarinda Wei Ling Chua Matthew Chau Hsien Ng Khee Chee Soo Melissa Ching Ching Teo | 2017 | World Journal of Gastrointestinal Oncology2017，9，3： | 6 |
| 14 | A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease显示文摘AIM: To assess the efficacy of combined Aliskiren and Losartan vs high dose Losartan and Aliskiren alone in chronic kidney disease(CKD).METHODS: This is a retrospective study of 143 patients with non-diabetic CKD comparing combined Aliskiren(150 mg/d) with Losartan(100 mg/d) therapyvs High dose Angiotensin receptor blockers(ARB)(Losartan 200 mg/d) and the third group Aliskiren(150 mg/d) alone. This study involved only patient medical records. Entry criteria included those patients who had been treated with the above drugs for at least 36 mo within the 5 years period; other criteria included proteinuria of 1 g or more and or CKD Stage 3 at the start of the 36 mo period. The study utilised primary renal end points of estimated Glomerular Filtration Rate(e GFR) < 15 m L/min or end stage renal failure. RESULTS: Patients treated with high dose ARB compared to the other two treatment groups had significantly less proteinuria at the end of 36 mo(P < 0.007). All 3 groups had significant reduction of proteinuria(P < 0.043, P < 0.001). Total urinary protein was significantly different between the 3 groups over the 3-year study period(P = 0.008), but not e GFR. The changes in e GFR from baseline to each year were not significantly different between the 3 therapeutic groups(P < 0.119). There were no significant differences in the systolic and diastolic blood pressure between the 3 drug groups throughout the 3 years. The incidence of hyperkalemia(> 5.5 mmol/L) was 14.2%(7/49) in the Combined Aliskiren and ARB group, 8.7%(4/46) in the Aliskiren alone group and 6.3%(3/48) in the High dose ARB group(P < 0.001). CONCLUSION: This study in non-diabetic CKD patients showed that Combination therapy with Aliskiren and ARB was effective but was not safe as it was associated with a high prevalence of hyperkalaemia. | Keng-Thye Woo Hui-Lin Choong Kok-Seng Wong Han-Kim Tan Marjorie Foo Fook-Chong Stephanie Evan JC Lee Vathsala Anantharaman Grace SL Lee Choong-Meng Chan | 2013 | World Journal of Nephrology2013，2，4： | 1 |
| 15 | Deregulated MIR 335 that targets MAPK 1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia显示文摘 | Junli Yan Nan Jiang Gaofeng Huang Jim L.‐S. Tay Baohong Lin Chonglei Bi Grace S. Koh Zhenhua Li Joy Tan Tae‐Hoon Chung Yi Lu Hany Ariffin Shirley K. Y. Kham Allen E. J. Yeoh Wee‐Joo Chng | 2013 | Br J Haematol2013，，1： | 1 |
| 16 | A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia显示文摘Background and Aims:Pharmaceutical therapy for NASH is associated with lipid modulation,but the consensus on drug treatment is limited and lacks comparative analysis of effectiveness.A network meta-analysis was conducted to compare NASH drug classes in lipid modulation.Methods:Online databases were searched for randomized controlled trails(RCTs)evaluating NASH treatments in biopsy-proven NASH patients.Treatments were classified into four groups:(1)inflammation,(2)energy,(3)bile acids,and(4)fibro-sis based on the mechanism of action.A Bayesian network analysis was conducted with outcome measured by mean difference(MD)with credible intervals(Crl)and surface un-der the cumulative ranking curve(SUCRA).Results:Forty-four RCTs were included in the analysis.Bile acid modulat-ing treatments(MD:0.05,Crl:0.03-0.07)were the best treatment for improvement in high-density lipid(HDL)cho-lesterol,followed by treatments modulating energy(MD:0.03,Crl:0.02-0.04)and fibrosis(MD:0.01,Crl:−0.12 to 0.14)compared with placebo.The top three treatments for reduction in triglycerides were treatments modulating energy(MD:−0.46,Crl:−0.49 to−0.43),bile acids(MD:−0.22,Crl:−0.35 to−0.09),and inflammation(MD:−0.08,Crl:−0.13 to−0.03)compared with placebo.SUCRA found treatment modulating fibrosis(MD:−1.27,Crl:−1.76 to−0.79)was the best treatment for reduction in low-density lipid(LDL)cholesterol followed by treatment modulating in-flammation(MD:−1.03,Crl:−1.09 to−0.97)and energy(MD:−0.37,Crl:−0.39 to−0.34)compared with placebo,but LDL cholesterol was worsened by treatments modulat-ing bile acids.Conclusions:Network analysis comparing the class effects of dyslipidemia modulation in NASH found that treatment targets can include optimization of athero-genic dyslipidemia.Future studies are required to evaluate the cardiovascular outcomes. | Jieling Xiao Cheng-Han Ng Yip-Han Chin Darren Jun Hao Tan Wen-Hui Lim Grace Lim Jingxuan Quek Ansel Shao Pin Tang Kai-En Chan Rou-Yi Soong Nicholas Chew Benjamin Tay Daniel Q.Huang Nobuharu Tamaki Roger Foo Mark Y.Chan Mazen Noureddin Mohammad Shadab Siddiqui Arun J.Sanyaland Mark D.Muthiah | 2022 | Journal of Clinical and Translational Hepatology2022，10，6： | 0 |
| 17 | PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy显示文摘Mitophagy 是为损坏线粒体的特定的消除的选择 autophagy 的一种重要类型。(PINK1 )导致 PTEN 的通常认为的 kinase 蛋白质 1 催化 ubiquitin (Ub ) 的 phosphorylation 在 PINK1-Parkin-mediated mitophagy 的发作起一个关键作用。(PTEN-L ) 磷酸酶和 tensin 相当或相同的事物(PTEN ) 长是 PTEN 的最新识别的 isoform,与到它的 N 终点的 173 氨基酸的增加。这里,我们报导 PTEN-L 是经由它对 phosphorylated ubiquitin 的蛋白质磷酸酶活动的 mitophagy 的一个新奇否定管理者。我们发现 PTEN-L 在外部 mitochondrial 膜(OMM ) 本地化,而 PTEN-L 的删除支持, PTEN-L 的 overexpression 禁止, mitophagy 由各种各样的损坏线粒体的代理人导致了。机械学地, PTEN-L 能够有效地阻止 Parkin mitochondrial translocation,减少 Parkin phosphorylation,维持它的关上的不活跃的符合构造,并且禁止它的 E3 ligase 活动。更重要地, PTEN-L 在 vivo 减少 phosphorylated ubiquitin (pSer65-Ub ) 的水平,并且在 vitro,磷酸酶试金经由它的蛋白质磷酸酶活动证实那 PTEN-L dephosphorylates pSer65-Ub,独立于它的类脂化合物磷酸酶功能。一起拿,我们的调查结果为 ubiquitin 作为蛋白质磷酸酶表明 PTEN-L 的新奇功能,它抵抗在 mitophagy 正式就职和 mitophagy 的最终的抑制导致前馈控制机制的阻塞的调停 PINK1 的 ubiquitin phosphorylation。因此,理解 PTEN-L 的这新奇功能在控制 mitophagy 的分子的难题提供一关键错过片,在包括象 Parkinsons 那样的 neurodegenerative 混乱的许多重要人的疾病的一个批评过程疾病。 | Liming Wang Yik-Lam Cho Yancheng Tang Jigang Wang Jung-Eun Park Yajun Wu Chunxin Wang Yan Tong Ritu Chawla Jianbin Zhang Yin Shi Shuo Deng Guang Lu Yihua Wu Hayden Weng-Siong Tan Pornteera Pawijit Grace Gui-Yin Lim Hui-Ying Chan Jingzi Zhang Lei Fang Hanry Yu Yih-Cherng Liou Mallilankaraman Karthik Boon-Huat Bay Kah-Leong Lim Siu-Kwan Sze Celestial T. Yap Han-Ming Shen | 2018 | Cell Research2018，28，8： | 25 |
您所在的机构暂未开通此部分的功能，请联系管理员